strontium ranelate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4714 135459-87-9

Description:

MoleculeDescription

Synonyms:

  • strontium ranelate
  • osseor
  • bivalos
  • distrontium renelate
  • protelos
an uncoupling agent containing strontium prevents bone loss by depressing bone resorption & maintaining bone formation in estrogen-deficient rats
  • Molecular weight: 513.49
  • Formula: C12H6N2O8SSr2
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 187.55
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 2004 EMA Les Laboratoires Servier

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metaphyseal corner fracture 66.51 28.97 8 838 32 46685184
Tibia fracture 48.09 28.97 12 834 4477 46680739
Drug reaction with eosinophilia and systemic symptoms 45.99 28.97 18 828 29530 46655686
Atypical fracture 38.82 28.97 7 839 551 46684665

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC M05BX03 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Other drugs affecting bone structure and mineralization
ATC M05BX53 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Other drugs affecting bone structure and mineralization
MeSH PA D050071 Bone Density Conservation Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Postmenopausal osteoporosis indication 102447009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C1721214 UMLSCUI
CHEMBL3707306 ChEMBL_ID
6918182 PUBCHEM_CID
C081587 MESH_SUPPLEMENTAL_RECORD_UI
DB09267 DRUGBANK_ID
04NQ160FRU UNII
010550 NDDF
432727001 SNOMEDCT_US
441487000 SNOMEDCT_US

Pharmaceutical products:

None